{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T21:17:47Z","timestamp":1783372667989,"version":"3.54.6"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009379","name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung, Universit\u00e4tsklinikum W\u00fcrzburg","doi-asserted-by":"publisher","award":["Z-2\/CSP-32"],"award-info":[{"award-number":["Z-2\/CSP-32"]}],"id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009379","name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung, Universit\u00e4tsklinikum W\u00fcrzburg","doi-asserted-by":"publisher","award":["Z-3BC\/08"],"award-info":[{"award-number":["Z-3BC\/08"]}],"id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the efficacy of somatostatin receptor (SSTR)-directed PET\/CT in localizing phosphaturic mesenchymal tumors (PMT) in patients with suspected tumor-induced osteomalacia (TIO) and to explore relationships between imaging parameters and biochemical markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective analysis included 20 patients with suspected TIO, undergoing SSTR-directed PET\/CT. Imaging findings and laboratory markers were assessed. SSTR-positive tumors were resected, while patients without detectable tumor, but persistent renal phosphate wasting, continued on medical treatment. Follow-up assessments included laboratory values and clinical examinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      PMT were detected on PET in 12 patients (60%), were resected, and confirmed immunohistochemically. Phosphorus levels (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.26;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03), tubular reabsorption of phosphate (TRP;\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.77;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) and tubular maximum of phosphate reabsorption over GFR (TmP\/GFR;\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.44;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.07) were lower in patients with detected PMT compared to those without. Elevation of fibroblast growth factor 23 (FGF23) was not significantly higher in PMT positive vs negative patients (253% vs 134% above the upper limit of normal;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.97). Total lesion uptake (TLU) negatively correlated with TmP\/GFR (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009-0.71;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03). A maximum standardized uptake value (SUVmax) threshold of 7.6 differentiated PMT from bone fractures (83% sensitivity; 100% specificity). Post-resection follow-up confirmed clinical cure in all cases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In SSTR-directed PET\/CT, a distinction between PMT and bone fracture may be possible with a SUVmax threshold of 7.6. The integration of PET derived TLU, along with TmP\/GFR may improve diagnosis and treatment planning for TIO.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11307-026-02101-z","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:58:48Z","timestamp":1777924728000},"page":"513-522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic Performance of Somatostatin Receptor-directed PET\/CT for Tumor-induced Osteomalacia"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3526-8601","authenticated-orcid":false,"given":"Marieke","family":"Heinrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9313-9356","authenticated-orcid":false,"given":"Aleksander","family":"Kosmala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dierks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6233-4805","authenticated-orcid":false,"given":"Franca","family":"Genest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2134-2774","authenticated-orcid":false,"given":"Elena","family":"Gerhard-Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8714-327X","authenticated-orcid":false,"given":"Lukas","family":"Haug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Achtziger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6063-5831","authenticated-orcid":false,"given":"Peter","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6447-0613","authenticated-orcid":false,"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7536-2207","authenticated-orcid":false,"given":"Constantin","family":"Lapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8715-7788","authenticated-orcid":false,"given":"Kerstin","family":"Michalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1154-3388","authenticated-orcid":false,"given":"Lothar","family":"Seefried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"issue":"2","key":"2101_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1210\/endrev\/bnac026","volume":"44","author":"S Minisola","year":"2023","unstructured":"Minisola S, Fukumoto S, Xia W, Corsi A, Colangelo L, Scillitani A et al (2023) Tumor-induced osteomalacia: a comprehensive review. Endocr Rev 44(2):323\u2013353","journal-title":"Endocr Rev"},{"key":"2101_CR2","doi-asserted-by":"crossref","unstructured":"Dahir K, Zanchetta MB, Stanciu I, Robinson C, Lee JY, Dhaliwal R, et al (2021) Diagnosis and management of tumor-induced osteomalacia: perspectives from clinical experience. J Endocr Soc 5(9)","DOI":"10.1210\/jendso\/bvab099"},{"issue":"7","key":"2101_CR3","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s11136-020-02465-x","volume":"29","author":"SH Lo","year":"2020","unstructured":"Lo SH, Lachmann R, Williams A, Piglowska N, Lloyd AJ (2020) Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study. Qual Life Res 29(7):1883\u20131893","journal-title":"Qual Life Res"},{"issue":"4","key":"2101_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00223-022-01005-8","volume":"111","author":"A Bosman","year":"2022","unstructured":"Bosman A, Palermo A, Vanderhulst J, De Beur SMJ, Fukumoto S, Minisola S et al (2022) Tumor-induced osteomalacia: a systematic clinical review of 895 cases. Calcif Tissue Int 111(4):367\u201379","journal-title":"Calcif Tissue Int"},{"key":"2101_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116077","volume":"152","author":"C Crotti","year":"2021","unstructured":"Crotti C, Bartoli F, Coletto LA, Manara M, Marini E, Daolio PA et al (2021) Tumor induced osteomalacia: A single center experience on 17 patients. Bone 152:116077","journal-title":"Bone"},{"issue":"3","key":"2101_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s12020-022-03039-2","volume":"76","author":"L Cianferotti","year":"2022","unstructured":"Cianferotti L, Delli Poggi C, Bertoldo F, Caffarelli C, Crotti C, Gatti D et al (2022) Persistence and recurrence in tumor-induced osteomalacia: A systematic review of the literature and results from a national survey\/case series. Endocrine 76(3):709\u201321","journal-title":"Endocrine"},{"key":"2101_CR7","doi-asserted-by":"crossref","unstructured":"Jan de Beur SM, Minisola S, Xia WB, Abrahamsen B, Body JJ, Brandi ML, et al (2023) Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia. J Intern Med 293(3):309\u201328","DOI":"10.1111\/joim.13593"},{"issue":"1","key":"2101_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.44","volume":"3","author":"S Minisola","year":"2017","unstructured":"Minisola S, Peacock M, Fukumoto S, Cipriani C, Pepe J, Tella SH et al (2017) Tumour-induced osteomalacia. Nat Rev Dis Primers 3(1):1\u201315","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"2101_CR9","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1210\/jc.2016-2052","volume":"101","author":"D El-Maouche","year":"2016","unstructured":"El-Maouche D, Sadowski SM, Papadakis GZ, Guthrie L, Cottle-Delisle C, Merkel R et al (2016) (68)Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J Clin Endocrinol Metab 101(10):3575\u20133581","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2101_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1210\/jc.2012-3642","volume":"98","author":"RJ Clifton-Bligh","year":"2013","unstructured":"Clifton-Bligh RJ, Hofman MS, Duncan E, Sim Ie W, Darnell D, Clarkson A et al (2013) Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET\/CT. J Clin Endocrinol Metab 98(2):687\u2013694","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2101_CR11","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1016\/j.humpath.2013.07.016","volume":"44","author":"M Houang","year":"2013","unstructured":"Houang M, Clarkson A, Sioson L, Elston MS, Clifton-Bligh RJ, Dray M et al (2013) Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum Pathol 44(12):2711\u20132718","journal-title":"Hum Pathol"},{"issue":"3","key":"2101_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s12149-021-01575-x","volume":"35","author":"A Kato","year":"2021","unstructured":"Kato A, Nakamoto Y, Ishimori T, Hayakawa N, Ueda M, Temma T et al (2021) Diagnostic performance of (68)Ga-DOTATOC PET\/CT in tumor-induced osteomalacia. Ann Nucl Med 35(3):397\u2013405","journal-title":"Ann Nucl Med"},{"issue":"1","key":"2101_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/cen.12426","volume":"81","author":"S Jadhav","year":"2014","unstructured":"Jadhav S, Kasaliwal R, Lele V, Rangarajan V, Chandra P, Shah H et al (2014) Functional imaging in primary tumour-induced osteomalacia: relative performance of FDG PET\/CT vs somatostatin receptor-based functional scans: a series of nine patients. Clin Endocrinol (Oxf) 81(1):31\u201337","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9308","key":"2101_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0140-6736(02)07846-7","volume":"359","author":"SM Jan de Beur","year":"2002","unstructured":"Jan de Beur SM, Streeten EA, Civelek AC, McCarthy EF, Uribe L, Marx SJ et al (2002) Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359(9308):761\u20133","journal-title":"Lancet"},{"issue":"3","key":"2101_CR15","first-page":"187","volume":"5","author":"D Kaemmerer","year":"2012","unstructured":"Kaemmerer D, Peter L, Lupp A, Schulz S, S\u00e4nger J, Baum RP et al (2012) Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol 5(3):187\u2013194","journal-title":"Int J Clin Exp Pathol"},{"issue":"3","key":"2101_CR16","first-page":"138","volume":"8","author":"W Remmele","year":"1987","unstructured":"Remmele W, Stegner HE (1987) [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 8(3):138\u201340","journal-title":"Pathologe"},{"issue":"1","key":"2101_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2967\/jnumed.123.266393","volume":"65","author":"AM Spektor","year":"2024","unstructured":"Spektor AM, Gutjahr E, Lang M, Glatting FM, Hackert T, Pausch T et al (2024) Immunohistochemical FAP expression reflects (68)Ga-FAPI PET imaging properties of low- and high-grade intraductal papillary mucinous neoplasms and pancreatic ductal adenocarcinoma. J Nucl Med 65(1):52\u201358","journal-title":"J Nucl Med"},{"issue":"11","key":"2101_CR18","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.3390\/cancers14112609","volume":"14","author":"A Kosmala","year":"2022","unstructured":"Kosmala A, Serfling SE, Dreher N, Lindner T, Schirbel A, Lapa C et al (2022) Associations between normal organs and tumor burden in patients imaged with fibroblast activation protein inhibitor-directed positron emission tomography. Cancers 14(11):2609","journal-title":"Cancers"},{"issue":"1","key":"2101_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ (1950) Index for rating diagnostic tests. Cancer 3(1):32\u201335","journal-title":"Cancer"},{"issue":"7","key":"2101_CR20","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1007\/s00259-011-1760-x","volume":"38","author":"C Boy","year":"2011","unstructured":"Boy C, Heusner TA, Poeppel TD, Redmann-Bischofs A, Unger N, Jentzen W et al (2011) 68Ga-DOTATOC PET\/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging 38(7):1224\u201336","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2101_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-54599-4","volume":"14","author":"JY Kim","year":"2024","unstructured":"Kim JY, Kim J, Kim YI, Yang DH, Yoo C, Park IJ et al (2024) Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors. Sci Rep 14(1):4047","journal-title":"Sci Rep"},{"issue":"2","key":"2101_CR22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1210\/endrev\/bnac026","volume":"44","author":"S Minisola","year":"2022","unstructured":"Minisola S, Fukumoto S, Xia W, Corsi A, Colangelo L, Scillitani A et al (2022) Tumor-induced osteomalacia: a comprehensive review. Endocr Rev 44(2):323\u201353","journal-title":"Endocr Rev"},{"key":"2101_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010436","author":"U Kumar","year":"2023","unstructured":"Kumar U (2023) Somatostatin and somatostatin receptors in tumour biology. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25010436","journal-title":"Int J Mol Sci"},{"key":"2101_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14071394","author":"S Priyadarshini","year":"2022","unstructured":"Priyadarshini S, Allison DB, Chauhan A (2022) Comprehensive assessment of somatostatin receptors in various neoplasms: a systematic review. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics14071394","journal-title":"Pharmaceutics"},{"issue":"10","key":"2101_CR25","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1007\/s00259-018-3971-x","volume":"45","author":"M Paquet","year":"2018","unstructured":"Paquet M, Gauth\u00e9 M, Zhang Yin J, Nataf V, B\u00e9lissant O, Orcel P et al (2018) Diagnostic performance and impact on patient management of (68)Ga-DOTA-TOC PET\/CT for detecting osteomalacia-associated tumours. Eur J Nucl Med Mol Imaging 45(10):1710\u20131720","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2101_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116064","volume":"152","author":"ML Brandi","year":"2021","unstructured":"Brandi ML, Clunie GPR, Houillier P, Jan de Beur SM, Minisola S, Oheim R et al (2021) Challenges in the management of tumor-induced osteomalacia (TIO). Bone 152:116064","journal-title":"Bone"},{"key":"2101_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2024.100600","volume":"45","author":"S Liu","year":"2024","unstructured":"Liu S, Zhou X, Liu Y, Zhang J, Xia W (2024) Preoperative evaluation and orthopedic surgical strategies for tumor-induced osteomalacia. J Bone Oncol 45:100600","journal-title":"J Bone Oncol"},{"issue":"1","key":"2101_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2967\/jnmt.121.263776","volume":"51","author":"RV Parghane","year":"2023","unstructured":"Parghane RV, Basu S (2023) False-positive (68)Ga-DOTATATE PET\/CT findings in hereditary hypophosphatemia-osteomalacia mimicking culprit lesions of tumor-induced osteomalacia. J Nucl Med Technol 51(1):73\u201374","journal-title":"J Nucl Med Technol"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-026-02101-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-026-02101-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-026-02101-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T21:09:51Z","timestamp":1783372191000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-026-02101-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2101"],"URL":"https:\/\/doi.org\/10.1007\/s11307-026-02101-z","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The local Ethics Committee of Julius-Maximilians University, Wuerzburg, Germany waived the need for further approval due to the retrospective character of the study (waiver no. 20241002 01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Lothar Seefried has received honoraria for consultation and lectures from Alexion\/AstraZeneca, AM-Pharma, Amgen, Biomarin, Chiesi, Gedeon-Richter, Haleon\/GSK, Inozyme, KyowaKirin, Mereo, Novartis, Stadapharm, Theramex, UCB and Ultragenyx; and grants for scientific projects to the institution from Alexion\/AstraZeneca, Chiesi, and KyowaKirin.\u00a0Franca Genest received speaker honoraria from Abbvie, Alexion, Lilly.\u00a0Constantin Lapa reports prior consulting activities for Blue Earth Diagnostics Ltd., PentixaPharm, Pfizer, and Novartis.\u00a0Kerstin Michalski reports prior consulting activities for Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}